GET THE APP

Cost Variation Analysis of Oral Anti-Diabetic Drugs Currentl | 113889

Jornal de Diabetes e Metabolismo

ISSN - 2155-6156

Abstrato

Cost Variation Analysis of Oral Anti-Diabetic Drugs Currently Available In the Indian Pharmaceutical Market

Khadga Raj Aran1*, Shamsher Singh2, G.D. Gupta3

Diabetes mellitus (DM) is chronic conditions that affects millions of people throughout the globe and are expected to take medicines for longer time and even medicines for life time are often needed to treat this disease. Costly branding of pharmaceuticals supplied in these circumstances adds to the burden of disease and may even result in therapeutic nonadherence. Thus, the research work was designed to determine the cost of anti-diabetic medicine from various brands. The cost of different brands of anti-diabetic medicines was calculated by referring to the IDR. The cost of each brand 7 tablets in INR, cost ratio and percentage cost variance was also determined. The difference between the highest and lowest cost of the same drug produced by various pharmaceutical companies was measured, and percentage variance was also calculated in cost for 7 tablets. The cost of total 7 anti-diabetic medicines was analyzed. There is more variation in the prices of different brands of same anti-diabetic medicines in the India market. The highest % cost variation was found for Pioglitazone 15 mg (185.7%), Tolbutamide 500 mg tablet (180 %), Glipizide 5 mg (157.2 %), Voglibose 0.2 mg (157.2%), Metform 500 mg (124.21%), Bromocriptine 2.5 mg (118.3%) and lowest % cost variation was of Acarbose 25 mg (117.18%).

Isenção de responsabilidade: Este resumo foi traduzido usando ferramentas de inteligência artificial e ainda não foi revisado ou verificado